Johnson & Johnson
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1886-01-01
- Employees
- 131.9K
- Market Cap
- $392.2B
- Website
- http://www.jnj.com
- Introduction
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Opdivo gets 'perioperative' approval; pharmas cut jobs in New Jersey, Ireland
Bristol Myers Squibb's Opdivo gains FDA approval for perioperative use in early-stage non-small cell lung cancer. Johnson & Johnson plans to invest $2 billion in a new biologics manufacturing facility in North Carolina. J&J, Bayer, and Bristol Myers Squibb are cutting jobs in New Jersey, while Pfizer plans to cut 210 jobs in Ireland. The WHO recommends RSV vaccination for pregnant women and antibody treatment for infants. Frazier Life Sciences raises $630 million for its evergreen Public Fund.
A Conversation With Luke Greenwalt, MBA
Greenwalt, a pharmaceutical market analyst, discusses his 25-year career, spanning sales, marketing, and market access, and his current role leading IQVIA's market access team. He highlights the challenges of product access in the U.S., including margin compression and the Inflation Reduction Act, and the complexities of biosimilar market success. Greenwalt also touches on the evolving role of GLP-1s in obesity treatment and the potential impact of the Inflation Reduction Act on pharmaceutical innovation and pricing.
Alzheimer's Disease Clinical Trials 2024: EMA, PDMA, FDA
DelveInsight's 2024 Alzheimer's Disease Pipeline Insight report details 110+ companies developing 120+ therapies, including Neurodon, Sangamo Therapeutics, and others. Key therapies like NRDN-201, ST-501, and Blarcamesine are in various clinical phases. Regulatory milestones include FDA's conventional approval of Leqembi in 2023. The report covers drug mechanisms, clinical studies, and market dynamics.
Promising Phase I results for Parkinson's disease cell therapy
A $110 million deal between Prime Medicine and Bristol Myers Squibb aims to develop next-gen T-cell therapies using Prime's PASSIGE technology. BlueRock Therapeutics reports positive 24-month data from its Phase I Parkinson's disease cell therapy trial, showing sustained benefits. Johnson & Johnson's CARVYKTI significantly extends survival in multiple myeloma patients, reducing the risk of death by 45% compared to standard therapies.
Johnson & Johnson plans $2B North Carolina plant
Johnson & Johnson is investing $2 billion in a biologics manufacturing facility in Wilson, North Carolina, to support its drug portfolio and planned therapy and product expansions by 2030. The facility will create 420 full-time jobs and is set to begin construction in the first half of next year.
Precision for Medicine, J&J, Bayer, IGM and more
Yosi Health appoints Lori Ryan as Director of Customer Success and Patrick McInnis as VP of Partnerships. Precision for Medicine hires Margaret Keegan as CEO, succeeding Mark Clein as Executive Chairman. Cosmo Pharmaceuticals names Egle Gedrimaite Head of Global Business Development. Sumitomo Pharma America appoints Kenton Stewart as its first CCO. IGM elevates Mary Beth Harler to CEO. Pangea Biomed adds Dr. Kenneth D. Aldape to its scientific advisory board. Johnson & Johnson, Bayer, Pfizer, and CVS Health announce layoffs.
Immunomodulators Market Size to Worth Around US$ 1,237.66 Bn by 2033
The global immunomodulators market is projected to grow from $317.06 billion in 2024 to $1,237.66 billion by 2034, driven by their use in treating autoimmune diseases, cancer, preventing infections, and managing organ transplant rejection. Key factors include advancements in precision medicine, regional growth in Asia-Pacific, and recent acquisitions and partnerships in the sector.
Triveni scores $115m to expand immunology pipeline
Triveni Bio secures $115m in Series B funding to advance preclinical antibody candidates for immunological and inflammatory diseases, including TRIV-573 targeting KLK5/7 and IL-13. Competitors like Johnson & Johnson are also active in the atopic dermatitis space. The bispecific antibody market is booming, with 1,147 oncology trials listed by GlobalData.
Eye on Pharma: High Strength Trastuzumab Biosimilar; Originator Coverage Removals
FDA approves 420 mg strength of Hercessi (trastuzumab-strf) biosimilar; UnitedHealth to remove Humira from preferred drug lists in favor of biosimilars; Evernorth offers interchangeable ustekinumab biosimilar at no cost; Samsung Bioepis receives positive opinion for aflibercept biosimilar.
ERLEADA® (apalutamide) demonstrates statistically significant and clinically ...
ERLEADA® (apalutamide) showed a 23% reduction in death risk at 24 months compared to enzalutamide in metastatic castration-sensitive prostate cancer patients, according to a real-world study presented at the 6th European Congress of Oncology Pharmacy.
Related Clinical Trials:
© Copyright 2024. All Rights Reserved by MedPath